DOCETAXEL-RZ docetaxel 20 mg/1 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel-rz docetaxel 20 mg/1 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel-rz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel-rz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel-rz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetaxel-rz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel-rz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetaxel-rz in c

DOCETAXEL-DRLA docetaxel 20 mg/1 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel-drla docetaxel 20 mg/1 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; polysorbate 80; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel-drla is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel-drla in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel-drla in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetaxel-drla in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel-drla in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetax

DOCETAXEL-DRLA docetaxel 80 mg/4 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel-drla docetaxel 80 mg/4 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; citric acid - breast cancer,metastatic breast cancer,docetaxel-drla is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel-drla in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel-drla in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetaxel-drla in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel-drla in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetax

DOCETERE docetaxel 20 mg/1 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetere docetaxel 20 mg/1 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; ethanol absolute; polysorbate 80 - breast cancer,metastatic breast cancer,docetere is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetere in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetere in combination with carbopla

DOCETAXEL-RZ docetaxel 80 mg/4 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel-rz docetaxel 80 mg/4 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol absolute; polysorbate 80; citric acid - breast cancer,metastatic breast cancer,docetaxel-rz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel-rz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel-rz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetaxel-rz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel-rz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetaxel-rz in c

Ionolyte sodium chloride, sodium acetate trihydrate, potassium chloride, magnesium chloride, Injection for intravenous infusion 1000 mL Freeflex bag Australia - English - Department of Health (Therapeutic Goods Administration)

ionolyte sodium chloride, sodium acetate trihydrate, potassium chloride, magnesium chloride, injection for intravenous infusion 1000 ml freeflex bag

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - ionolyte is indicated for:,- mild metabolic acidosis,- as a source of water and electrolytes

Ionolyte sodium chloride, sodium acetate trihydrate, potassium chloride, magnesium chloride, Injection for intravenous infusion 500 mL Freeflex bag Australia - English - Department of Health (Therapeutic Goods Administration)

ionolyte sodium chloride, sodium acetate trihydrate, potassium chloride, magnesium chloride, injection for intravenous infusion 500 ml freeflex bag

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - ionolyte is indicated for:,- mild metabolic acidosis,- as a source of water and electrolytes

Levetiracetam SUN levetiracetam 500mg/5mL concentrated injection vials Australia - English - Department of Health (Therapeutic Goods Administration)

levetiracetam sun levetiracetam 500mg/5ml concentrated injection vials

sun pharma anz pty ltd - levetiracetam, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: glacial acetic acid; water for injections; sodium chloride; sodium acetate trihydrate - levetiracetam (film-coated tablets and oral solution) is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam sun concentrated injection after dilution is an alternative for patients when oral administration is temporarily not feasible.

DBL ACETYLCYSTEINE injection concentrate acetylcysteine 2 g/ 10 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

dbl acetylcysteine injection concentrate acetylcysteine 2 g/ 10 ml injection ampoule

pfizer australia pty ltd - acetylcysteine, quantity: 2 g - injection, concentrated - excipient ingredients: water for injections; disodium edetate; sodium hydroxide - as an antidote for paracetamol poisoning: acetylcysteine injection concentrate is indicated in the treatment of paracetamol overdose to protect against hepatotoxicity.

ASPEN CIPROFLOXACIN ciprofloxacin injection for intravenous infusion 200mg/100mL bag Australia - English - Department of Health (Therapeutic Goods Administration)

aspen ciprofloxacin ciprofloxacin injection for intravenous infusion 200mg/100ml bag

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.